Entropy increases in kidney cancer treatment, but a bit of simplicity may emerge from chaos

European Urology

Volumn 60, Issue 6, 2011, Pages 1171-1172

  Porta, Camillo ^a,b  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b GION Gruppo Italiano di Oncologia Nefrologica   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; AXITINIB; BEVACIZUMAB; EVEROLIMUS; PAZOPANIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TIVOZANIB; VON HIPPEL LINDAU PROTEIN;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL PRACTICE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; EDITORIAL; ENTROPY; GENE MUTATION; HUMAN; KIDNEY CANCER; LOW DRUG DOSE; MOLECULARLY TARGETED THERAPY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TUMOR SUPPRESSOR GENE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 80255138154     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2011.07.058     Document Type: Editorial

References (10)

1. S. Négrier, G. Gravis, and D. Pérol Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial Lancet Oncol 12 2011 673 680
2. Melichar B, Bracarda S, Matveev V, et al. BEVLiN: prospective study of the safety and efficacy of first-line bevacizumab (BEV) plus low-dose interferon-α2a (IFN) in patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2011;29, abstract 4546.
3. B. Melichar, P. Koralewski, and A. Ravaud First-line bevacizumab combined with reduced dose interferon-alpha2a is active in patients with metastatic renal cell carcinoma Ann Oncol 19 2008 1470 1476
4. B. Escudier, C. Szczylik, and T.E. Hutson Randomized phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma J Clin Oncol 27 2009 1280 1289
5. Rini BI, Szczylik C, Tannir NM, et al. AMG 386 in combination with sorafenib in patients (pts) with metastatic renal cell cancer (mRCC): a randomized, double-blind, placebo-controlled, phase II study. J Clin Oncol 2011; 29(Suppl 7), abstract 309.
6. Porta C, Szczylik C, Escudier B. Combination or sequencing strategies to improve the outcome of metastatic renal cell carcinoma patients: a critical review. Crit Rev Oncol Hematol. In press.
7. J. Busch, C. Seidel, and C. Kempkensteffen Sequence therapy in patients with metastatic renal cell carcinoma: comparison of common targeted treatment options following failure of receptor tyrosine kinase inhibitors Eur Urol 60 2011 1163 1170
8. C. Porta, C. Paglino, and I. Imarisio Sequencing tyrosine kinase inhibitors or immediately switching to mTOR inhibitors in advanced kidney cancer: a critical review Eur J Med Clin Oncol 2 2011 67 72
9. B.I. Rini New strategies in kidney cancer: therapeutic advances through understanding the molecular basis of response and resistance Clin Cancer Res 16 2010 1348 1354
10. Baranger M. Chaos, complexity, and entropy. A physics talk for non-physicists. New England Complex Systems Institute Web site. http://necsi.edu/projects/baranger/cce.pdf.